Cargando…
Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
BACKGROUND: This study was aimed to detect post-chemotherapeutic circulating tumour cells (CTCs) in stage III colon cancer patients and identify those who were at high risk of relapse. METHODS: We used human telomerase reverse transcriptase, cytokeratin-19, cytokeratin-20, and carcinoembryonic antig...
Autores principales: | Lu, C-Y, Tsai, H-L, Uen, Y-H, Hu, H-M, Chen, C-W, Cheng, T-L, Lin, S-R, Wang, J-Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590657/ https://www.ncbi.nlm.nih.gov/pubmed/23422758 http://dx.doi.org/10.1038/bjc.2012.595 |
Ejemplares similares
-
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013) -
mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
por: Matsunaga, Mototsugu, et al.
Publicado: (2016) -
A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report
por: Sonoda, Hiromichi, et al.
Publicado: (2014) -
Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022) -
The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)